Shares of DBV Technologies (DBVT) are moving lower after the company a “substantial doubt regarding its ability to continue as a going concern.” When reporting unaudited results for 2024 ...

American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million. The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a ...